Ryan White Care Hepatitis C & B Language
NATAP Webinars:
Check Back Soon for Our 2026 Webinars
View all archived NATAP webinars here
Current HIV Articles and News Updates
HIV
Oral Daily Bictregavir+Lenacapavir
- (01/06/26)
Low-level viremia linked to virological failure but not clinical events
- (01/05/26)
Islatravir (+doravirine), nucleoside-sparing, oral daily and long-acting new ART regimens; Monthly PrEP; Weekly (NNRTI), Weekly with Lenacapavr
- (01/05/26)
Weekly Oral Islatravir+MK-8507 (Ulonivirine NNRTI)
- (01/05/26)
More HIV Articles...
Hepatitis D
HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines
AASLD:
Elevations in Total Serum Bile Acids During Bulevirtide Treatment Are Asymptomatic and Not Associated With Adverse Events of Interest in Patients With Chronic Hepatitis Delta
- (11/20/25)
AASLD:
Patient-Reported Burden and Health-Related Quality of Life Among Patients With Hepatitis Delta: Results From a Real-World Study in Europe
- (11/20/25)
AASLD:
Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide 10 mg Once Daily for 6 Days in Participants With Severe Hepatic Impairment and in Matched Control Participants With Normal Hepatic Function
- (11/20/25)
More Hep D Articles...
Aging & Perinatally Acquired HIV
Frailty and All-Cause Mortality among People with HIV Engaged in Clinical Care in the United States
- (12/29/25)
Evolution of Causes of Death in People With HIV Between 2000 and 2023: A Single-Center Retrospective Study in Milan, Italy
- (12/29/25)
More Aging & HIV Articles...
PrEP
Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention
- (01/09/26)
ID Week:
Real-World Persistence to Long-Acting Cabotegravir Versus Oral PrEP for HIV Prevention in Participants Using a Digital Health Companion Tool (AURORA Study)
- (11/04/25)
More PreP Articles...
Current Hepatitis C and B Articles
Hepatitis C
Long-term liver stiffness dynamics after sustained virological response in patients with HIV/HCV co-infection and advanced fibrosis
- (01/09/26)
A single-arm phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C
- (12/22/25)
AASLD:
Multiscale modeling of results from a phase 2 study of an 8-week combination regimen of Bemnifosbuvir and Ruzasvir in patients with chronic hepatitis C virus infection
- (11/25/25)
AASLD:
No Impact of RASs on the High Efficacy of BEM and RZR in Combination: Resistance Analysis from a Phase 2 Study in HCV-infected Patients
- (11/25/25)
AASLD:
Bemnifosbuvir and Ruzasvir Provided as a Fixed-Dose Combination Demonstrates High Relative Bioavailability to Their Individual Formulations and Can Be Dosed With No Regard to Food
- (11/25/25)
More Hep C Articles...
Hepatitis B
HBV Patient Declaration of Rights
-
AASLD:
Safety, Pharmacokinetics, and Antiviral Activity of the Next-Generation Hepatitis B Capsid Assembly Modulator ABI-4334 in Patients With HBeAg-Negative Chronic Hepatitis B Infection Not Suppressed on Nucleoside Analogues: Results From a Randomized, Blinded, Phase 1b Study
- (12/29/25)
AASLD:
Impact of Baseline HBeAg Status on HBV Outcomes in the ALLIANCE Study
- (11/24/25)
AASLD:
Characterization of HIV/HBV Co-infected Participants Achieving High Rates of Hepatitis B Surface Antigen (HBsAg) Loss in the ALLIANCE Phase 3 Clinical Study
- (11/24/25)
More Hep B Articles...
Fatty Liver, NAFLD, NASH, MASLD, MASH
A Phase 2b, Multicenter, Randomized, Placebo- Controlled Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis
- (12/29/25)
Reduction of Liver Fibrosis by Al-Based Digital Pathology Analysis: Results from the Pemvidutide Phase 2b IMPACT Trial
- (12/29/25)
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
- (12/29/25)
More Fatty Liver Articles...
Check Out Our Special NATAP Features
List not necessarily listed here in order of date being held.
https://academicmedicaleducation.com/meeting/2nd-african-workshop-women-hiv-2025
https://academicmedicaleducation.com/meeting/2nd-menopause-hiv-webinar-2025
https://www.croiconference.org
https://academicmedicaleducation.com/meeting/15th-international-workshop-women-hiv-2025
https://acthiv.org/
https://ddw.org/
https://www.easlcongress.eu/
https://asm.org/Events/ASM-Microbe/Home
IAS 2025, the 13th IAS Conference on HIV Science,
Kigali, Rwanda, July 13 to 17,
pre-conferences on 13 July.
https://www.iasociety.org/conferences/ias2025
https://academicmedicaleducation.com/meeting/26th-international-workshop-clinical-pharmacology-hiv-hepatitis-and-other-antiviral-drugs
https://academicmedicaleducation.com/meeting/11th-international-viral-hepatitis-elimination-meeting-ivhem-2025
https://academicmedicaleducation.com/meeting/8th-conference-liver-disease-africa-colda-2025
https://www.eacsociety.org/european-aids-conference/european-aids-conference/
https://idweek.org/
https://academicmedicaleducation.com/meeting/16th-international-workshop-hiv-aging-2025
https://www.aasld.org/the-liver-meeting
https://neurohiv.com/
